Mount Sinai Researchers Unveil New Targets for Depression at
Neuroscience 2012 Scientists presented important discoveries on
the involvement of the immune system and dopamine on the onset
of depression. Researchers from Mount Sinai School of Medicine
presented important discoveries on the involvement of the immune
system and dopamine cells in the onset of depression at
Neuroscience 2012, the Society for Neuroscience's 42nd annual
meeting on October 13 -17 in New Orleans. In addition to
scientists presenting at the conference, Dennis S. Charney, MD,
Anne and Joel Ehrenkranz Dean, Mount Sinai School of Medicine,
Executive Vice President for Academic Affairs, The Mount Sinai
Medical Center, is available to speak about depression and the
psychobiological mechanisms of human resistance to stress. As a
renowned expert in the neurobiology and treatment of mood and
anxiety disorders, he has led research teams that have
discovered that ketamine is a rapidly-acting drug in patients
with treatment-resistant depression.